Abstract
Vitamin D deficiency is a well-established risk factor for bone disease. Emerging data suggest a pleiotropic role of this agent in a variety of functions in humans. Epidemiological studies indicate an inverse association between vitamin D deficiency and the prevalence of cardiovascular disease (CVD), as well as individual cardiometabolic risk factors, such as hypertension, diabetes, dyslipidemia and the metabolic syndrome. Moreover, vitamin D deficiency has been implicated in the atherosclerotic process.
This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes.
Keywords: Vitamin D, cardiovascular disease, hypertension, diabetes mellitus, metabolic syndrome
Current Vascular Pharmacology
Title: Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Volume: 8 Issue: 5
Author(s): Panagiotis Anagnostis, Vasilios G. Athyros, Fotini Adamidou, Matilda Florentin and Asterios Karagiannis
Affiliation:
Keywords: Vitamin D, cardiovascular disease, hypertension, diabetes mellitus, metabolic syndrome
Abstract: Vitamin D deficiency is a well-established risk factor for bone disease. Emerging data suggest a pleiotropic role of this agent in a variety of functions in humans. Epidemiological studies indicate an inverse association between vitamin D deficiency and the prevalence of cardiovascular disease (CVD), as well as individual cardiometabolic risk factors, such as hypertension, diabetes, dyslipidemia and the metabolic syndrome. Moreover, vitamin D deficiency has been implicated in the atherosclerotic process.
This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes.
Export Options
About this article
Cite this article as:
Anagnostis Panagiotis, G. Athyros Vasilios, Adamidou Fotini, Florentin Matilda and Karagiannis Asterios, Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792006978
DOI https://dx.doi.org/10.2174/157016110792006978 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects:A Meta-Analysis
Current Vascular Pharmacology Downstream Processing of Bioactive Compounds from Milk and Whey
Current Biochemical Engineering (Discontinued) Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Current Pharmaceutical Design Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Editorial (Forward Look: Tenth Anniversary of the Human Genome Sequence and 21st Century Postgenomics Global Health - A Close Up on Africa and Womens Health)
Current Pharmacogenomics and Personalized Medicine Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design The Use of Human Albumin for the Treatment of Ascites in Patients with Liver Cirrhosis: Item of Safety, Facts, Controversies and Perspectives
Current Drug Safety Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Brain Angiotensin II Involvement in Chronic Mental Disorders
Protein & Peptide Letters Vascular Arginase and Hypertension
Current Hypertension Reviews subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antidiabetic Oils
Current Diabetes Reviews Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Rho-Kinase as a Drug Target for the Treatment of Airway Hyperresponsiveness in Asthma
Mini-Reviews in Medicinal Chemistry Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design